title: Transcatheter arterial chemoembolization with paclitaxel-lipiodol solution in rabbit VX2 liver tumor.
abstract: OBJECTIVE
  To evaluate the antitumor effects of transcatheter arterial chemoembolization (TACE) with a solution of an anticancer drug (Paclitaxel; Bristol-Myers Squibb, Princeton, NJ) and iodized oil (Lipiodol; Laboratoire Gurerbet, Aulnay-Sous-Bois, France) (hereafter, the solution), as well as intratumor concentration and hepatotoxicity, in experimentally induced liver tumor.
  
  
  METHODS
  VX2 carcinoma was grown in livers of 30 rabbits. In 18 rabbits, TACE was performed with the high-dose solution (4 mg anticancer drug and 0.4 mL iodized oil, n = 6), the low-dose solution (1 mg anticancer drug and 0.4 mL iodized oil, n = 6), or iodized oil alone (0.4 mL, n = 6) in a control group. One week later, the growth ratio and residual viable proportion of the tumors were calculated on the basis of findings at spiral computed tomography and histopathologic examination. Hepatic and hematologic toxicities were evaluated by means of biochemical analysis. Differences between the three groups were statistically assessed with the Kruskal-Wallace and Mann-Whitney U tests. The remaining 12 animals were treated with the high-dose solution and serially sacrificed for clarification of chronologic change of concentration of the anticancer drug in liver tissues.
  
  
  RESULTS
  Growth ratios and residual viable proportions of the tumors were significantly lower in the solution groups (high dose, 3.3% +/- 6.2 [mean +/- SD] and 2.8% +/- 3.6, respectively; low dose, 18.7% +/- 7.4 and 12.7% +/- 6.1, respectively) than in the control group (68.3% +/- 12.7 and 31.1% +/- 8.8, respectively) (P <.05). Hepatotoxicity was transient in all but one rabbit, which died 2 days after TACE with substantial biochemical changes. The anticancer drug accumulated in tumor where the concentration peaked at day 3 and returned to levels comparable to those for normal hepatic parenchyma at 7 days after TACE.
  
  
  CONCLUSIONS
  TACE with the Paclitaxel-Lipiodol solution has dose-dependent antitumor effects without major toxicities in VX2 liver tumor.
authors.affiliation: Department of Radiology and the Institute of Radiation Medicine, Seoul National University College of Medicine, Clinical Research Institute, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Korea.
authors.forename: Chang Jin
authors.initials: CJ
authors.lastname: Yoon
authors.forename: Jin Wook
authors.initials: JW
authors.lastname: Chung
authors.forename: Jae Hyung
authors.initials: JH
authors.lastname: Park
authors.forename: Young Ho
authors.initials: YH
authors.lastname: Yoon
authors.forename: Joon Woo
authors.initials: JW
authors.lastname: Lee
authors.forename: Seo Young
authors.initials: SY
authors.lastname: Jeong
authors.forename: Hesson
authors.initials: H
authors.lastname: Chung
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000633:toxicity; D002406:Catheterization, Peripheral; D016461:Chemoembolization, Therapeutic / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers / Q000008:administration & dosage / Q000633:toxicity; D007459:Iodized Oil / Q000008:administration & dosage* / Q000633:toxicity; D008114:Liver Neoplasms, Experimental / Q000000981:diagnostic imaging / Q000628:therapy*; D009368:Neoplasm Transplantation; D017239:Paclitaxel / Q000008:administration & dosage* / Q000633:toxicity; D011817:Rabbits; D036542:Tomography, Spiral Computed
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D007459:Iodized Oil; D017239:Paclitaxel